Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.
- Sales 2012: 18,612 Euro million
- Workforce: 55,300 worldwide
- Operating profit 2012: 2,154 Euro million
- Headquarters: Leverkusen, Germany
Divisions of Bayer HealthCare
|Animal Health||Dr. Dirk Ehle||Monheim, Germany|
|Pharmaceuticals||Andreas Fibig||Berlin, Germany|
|Consumer Care||Erica L. Mann||Morristown, USA|
|Medical Care||Alan Main||Tarrytown, New York, USA|
The Pharmaceuticals segment consists of two business units focusing on prescription products:
- General Medicine, primarily comprising women’s healthcare and cardiovascular health products; and
- Specialty Medicine, comprising medicines that are mainly prescribed by specialist physicians.
Our Consumer Health segment includes the Consumer Care, Medical Care and Animal Health divisions.
The main focus of the Consumer Care Division is on non-prescription medicines, dietary supplements and dermatology products.
Medical Care comprises the businesses with blood glucose meters, contrast-enhanced diagnostic imaging equipment together with the necessary contrast agents, and mechanical systems for treating constricted or blocked blood vessels.
The products of the Animal Health Division are destined for use in livestock and companion animals.
Sales 2012Sales of the HealthCare subgroup rose by 4.2% (Fx & portfolio adj.) in 2012 to €18,612 million (reported: +8.4%), with both the Pharmaceuticals and the Consumer Health segments contributing to this growth. Business developed especially well in the emerging markets and in North America.
|€ million||€ million||%|
|- Division Animal Health
|- Division Consumer Care
|- Division Medical Care
|- Division Pharmaceuticals
Sales of the Pharmaceuticals segment in 2012 came in at €10,803 million, up 4.2% (Fx & portfolio
adj.) from the prior year. Growth was achieved mainly in North America and the emerging markets,
particularly China. There was no overall sales gain in Europe due to the adverse economic conditions
and a difficult health policy environment.
Our anticoagulant Xarelto™ contributed significantly to sales growth in the Pharmaceuticals segment. Sales advanced strongly in all regions – particularly in Germany, the United States and Japan – following further product launches and indication expansions.
Business with our hormone-releasing intrauterine device Mirena™ developed positively in all regions, especially in the United States due to higher volumes.
Sales of the blood-clotting product Kogenate™ advanced due to higher volumes that mainly resulted from tender business in Australia.
The growth in sales of our multiple sclerosis drug Betaferon™/ Betaseron™ was mainly attributable to price increases in the United States, while sales in other countries declined. Sales of the cancer drug Nexavar™ moved ahead, particularly in the United States and China and helped by tender business in Latin America.
Sales of Aspirin™ Cardio to prevent heart attacks and of our oral diabetes treatment Glucobay™ rose considerably, largely thanks to the steady expansion of our marketing activities in China.
Sales of Adalat™ to treat high blood pressure and coronary heart disease also rose strongly in China. However, Adalat™ sales posted a slight overall decline on a currency-adjusted basis, mainly as a result of mandatory price reductions in Japan.
Sales of our erectile dysfunction treatment Levitra™ and the antibiotic Avalox™/ Avelox™ were down, particularly in the United States, for reasons that included the partial restructuring of distribution for general medicine products. The decline for Avalox™/ Avelox™ was partly offset by higher sales to a major customer in Western Europe and business growth in China.
Sales of the YAZ™/ Yasmin™/Yasminelle™ line of oral contraceptives receded, primarily as a result of generic competition in Western Europe, although business developed positively in the Asia / Pacific region.
Our Pharmaceuticals business was strengthened by initial sales of our cancer drug Stivarga™ (active ingredient: regorafenib) in the United States – 2012 sales: €32 million – and of Eylea™ (active ingredient: aflibercept) to treat wet age-related macular degeneration – 2012 sales: €14 million.
Sales of the Consumer Health segment in 2012 advanced by 4.2% (Fx & portfolio adj.) to €7,809 million, with all regions and divisions contributing to sales growth. The Consumer Care business showed a particularly positive development in the emerging markets.
Our Consumer Care Division achieved above-market sales growth of 5.6% (Fx & portfolio adj.) to €3,853 million. The encouraging sales gains were mainly attributable to intensified marketing activities, which boosted sales of products such as our Bepanthen™/ Bepanthol™ skincare line, especially in Russia and Brazil, and the antifungal Canesten™, particularly in Germany.
The growth in sales of our analgesic Aleve™/ naproxen resulted mainly from higher volumes in the United States.
Sales of our pain-reliever Aspirin™ showed a small increase, largely as a result of new launches in the United States.
Sales of the Medical Care Division rose by 2.2% (Fx & portfolio adj.) to €2,653 million. The positive development of our Diabetes Care business – despite price and reimbursement pressure – contributed substantially to this increase. Sales growth was primarily attributable to the Contour™ line of blood glucose meters, which posted gains in all regions, mainly due to the launch of Contour™ Next.
Sales of our contrast agent and medical equipment business matched the prior year. In the area of contrast agents for magnetic resonance imaging (MRI), we raised sales of Gadovist™ / Gadavist™, particularly in the United States. This increase was partly due to the switch from Magnevist™, sales of which steadily receded.
The Animal Health Division lifted sales by 4.2% (Fx & portfolio adj.) to €1,303 million. Business with our Advantage™ line of flea, tick and worm control products developed particularly well in the United States and Europe.
Research & Development 2012
In 2012 we invested €1,962 million (2011: €1,948 million) in research and development in the Pharmaceuticals and Consumer Health segments. This amounted to 65.1% of the Bayer Group’s entire research and development spending and was equivalent to 10.5% (2011: 11.3%) of HealthCare sales. At the end of 2012, some 7,500 employees of the HealthCare subgroup were working in research and development.